ERBB2 and carcinoma: Exemplary studies for this patient population have documented that the proliferation marker Ki67 increases inversely proportionally to the patient’s age; G3 carcinomas are present in 60%, triple-negative carcinomas (TNBC) in 20%, and HER2-positive (non-luminal) carcinomas in 25% of cases.